Exosome-Based Pathological Microenvironment-Responsive Nanocapsules for Targeted Heart Repair
Exosome-Based Pathological Microenvironment-Responsive Nanocapsules for Targeted Heart Repair
批准号:
10193094
负责人:
Teng Su
金额:
$23.64万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-15 至 2023-03-31
关键词:
AddressAdultAgrinAmericanApplications GrantsAwardBiological AssayBiomedical EngineeringCardiacCardiac MyocytesCardiovascular systemCause of DeathCell ProliferationCell TherapyCellsClinicalElectrostaticsEngineeringEnzymesFibrosisFoundationsGrowth FactorHeartHeart InjuriesHumanIn VitroInflammationInjectionsInjuryInsulin-Like Growth Factor IMatrix MetalloproteinasesMediatingMedicineMesenchymal Stem CellsModelingMyelogenousMyocardialMyocardial InfarctionMyocardial IschemiaMyocardiumNatural regenerationPathologicPathologyProcessProteinsRattusResearch Project GrantsSafetySchemeSeriesSignal PathwaySignal TransductionSiteStromal CellsTechnologyTestingTherapeuticTissuesUnited StatesUp-RegulationVesiclebasecardiac regenerationcardiac repaircardioprotectioncost effectivedesignexosomeinjuredinjury and repairinnovationischemic injurynanocapsulenanoformulationnanomedicinenanosizednovelnovel strategiesparacrineparticlepolymerizationpre-clinicalregenerativerepairedresponsestemstem cell exosomesstem cell therapystem cellstargeted treatmenttherapeutic proteintissue repair
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The proposed research project addresses the need for a bioengineering approach to a smart and
targeted exosome-based therapeutic delivery platform that can promote tissue repair after myocardial infarction
(MI). Accumulating evidence in both preclinical and clinical settings has consistently indicated the exosomes
secreted from adult stem/stromal cells orchestrate the principal modes of action of cell therapy to repair the
injured heart muscle following MI. Exosome-based therapeutics represent a paradigm shift from conventional
cell-based approaches to cardiovascular therapy. However, current exosome-based therapeutics suffer from
several problems including lack of targetability, complicated fabrication process to load additional therapeutic
cargos, and expense. In addition, technologies that enable controlled delivery of exosome-based products have
yet to be explored. To overcome these challenges, we propose to develop a smart cardiotherapeutic
nanocapsule (CardioXo) for the targeted and controlled delivery of both mesenchymal stem cell-derived
exosomes (MSC-Exo) and therapeutic proteins to promote heart repair post-MI. Our central hypotheses are that
(1) the CardioXo functionalized with both exosomes and cardioprotective proteins (e.g., prokineticin 2, agrin,
insulin-like growth factor 1, myeloid-derived growth factor) can be engineered via an electrostatic layer-by-layer
assembly process combined with a novel enzyme-mediated radical polymerization (EMRP) technology; and (2)
the CardioXo can enable the delivery of combination therapeutics in response to the upregulation of matrix
metalloproteinases (MMPs), a hallmark of cardiac ischemic injury, and trigger the reparative signaling pathways
mediated by therapeutic proteins to repair the ischemic heart. The innovation of the proposed CardioXo strategy
includes (1) targeting to the injured cardiomyocytes; (2) ability to deliver combination therapeutics in an on-
demand fashion by leveraging cardiac pathology in the ischemic heart; (3) dual-regenerative mechanism for
targeted heart repair that combines the exosome-mediated paracrine mechanism similar to stem cell therapy
with the cardioprotective protein-mediated signaling pathways. We will fabricate and optimize the CardioXo
loaded with various cardioprotective proteins and assess the in vitro bioactivity of CardioXo. The safety,
functional benefits, and the potential modes of action of CardioXo therapy will be investigated in rats with
ischemic heart injury. Successful execution of the proposed research project will establish a mild and facile
approach to exosome functionalization and form the foundation of an innovative and off-the-shelf exosome-
based therapy based on smart and targeted nanomedicine for the repair and regeneration of the post-MI heart.
Although this particular grant application targets the heart, the CardioXo strategy represents a platform
technology that can be generalized to the repair and regeneration of multiple tissues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exosome-Based Pathological Microenvironment-Responsive Nanocapsules for Targeted Heart Repair
-
批准号:10382401
-
项目类别:
-
资助金额:$19.6万
-
财政年份:2021
-
负责人:Teng Su
-
依托单位:
海外基金